Stay updated with breaking news from ஒரினிய மருந்து. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
The increased loss came despite a $50-million deal with Japanese pharmaceutical firm Otsuka Pharmaceutical, which gave the Asian firm the right to develop and market Lupkynis in Europe and Asia. Aurinia also reported it had cash, cash equivalents and investments of $423 million US, an increase of $117 million compared with last year. In a statement, Aurinia said it has sufficient financial resources to fund its current plans, which include funding commercial launch, manufacturing and packaging of commercial drug supply and conducting research and development into at least 2023. Chief executive Peter Greenleaf said the company made strategic investments last year to build its commercial team, make the deal with Otsuka and secure manufacturing capacity to meet future demand. ....
Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis) in multiple sclerosis, Stelara (Janssen) in ulcerative colitis, Tremfya (Janssen) in psoriatic arthritis, and Benlysta (GSK) and Lupkynis (Aurinia) in lupus nephritis News provided by Share this article Share this article EXTON, Pa., Jan. 29, 2021 /PRNewswire/ Spherix Global Insights, a leading market intelligence firm specializing in select dermatology, gastroenterology, nephrology, neurology, and rheumatology markets, announces the inaugural publications of their newest service offering, ....
Lupus Research Alliance Hails Approval of Aurinia s Lupkynis(TM) (voclosporin) First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month News provided by Share this article Share this article NEW YORK, Jan. 22, 2021 /PRNewswire/ The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals Lupkynis TM (voclosporin) as the first oral treatment developed specifically for adults with active lupus nephritis (LN) in combination with standard of care. Voclosporin follows the recent approval of belimumab by the FDA as new therapies indicated for lupus nephritis – both within the past month. ....